Home Capital Broker's Calls

Clear skies for ClearBridge Health as PhillipCapital expects stronger recovery in 2H20

Lim Hui Jie
Lim Hui Jie8/31/2020 11:32 AM GMT+08  • 3 min read
Clear skies for ClearBridge Health as PhillipCapital expects stronger recovery in 2H20
PhillipCapital has maintained its “buy” rating and target price of 26 cents on ClearBridge Health on the back of a stronger 2H20 for the company.
Font Resizer
Share to WhatsappShare to FacebookShare to LinkedInMore Share
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

PhillipCapital has maintained its “buy” rating and target price of 26 cents on ClearBridge Health (CBH) on the back of a stronger 2H20 for the company.

The Phillip Research Team said 1H20 revenue and earnings before interest, taxes, depreciation, and amortization (EBITDA) were within expectations with revenue coming in at $21.4 million and EBITDA at a positive $3.6 million. Operating cashflow also saw a reversal from negative$3.6million in 1H19 to $4.5 million in 1H20.

They add CBH continues to expand and leverage its network of medical centres throughout ASEAN. The stronger operating cash-flow and balance sheet will allow CBH to further grow via acquisition and expand their Indonesian operations faster where the capital expenditure and working capital requirements are much higher.

×
Loading next article...
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
Subscribe to The Edge Singapore
Get credible investing ideas from our in-depth stock analysis, interviews with key executives, corporate movements coverage and their impact on the market.
© 2022 The Edge Publishing Pte Ltd. All rights reserved.